Compare Charles River Laboratories Intl. Inc (CRL) vs iShares MSCI Taiwan ETF (EWT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares MSCI Taiwan ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.72 (market cap $11.14B), while iShares MSCI Taiwan ETF trades at $102.05. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares MSCI Taiwan ETF nearer its low. Which is the better fit depends on your goals.
| CRL | EWT | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $111.53 |
52-Week Low | $145.57 | $58.05 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EWT, the iShares MSCI Taiwan ETF, trades at $101.88, down 4.04% on the day amid a bearish technical signal. The ETF has delivered strong returns in 2026, more than doubling from its 2025 close, driven by Taiwan's critical role in the global semiconductor and AI supply chain. However, key financial ratios are unavailable, and the technical outlook is mixed, with moving averages bullish but oscillators neutral.
The outlook for EWT is clouded by geopolitical tensions with China and potential currency volatility, though its exposure to the AI-driven semiconductor boom offers significant growth potential. Investors face a trade-off between high-reward tech exposure and substantial geopolitical risk, with the current price near key support levels suggesting a cautious near-term stance is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →
